New publication by Frimpong et al. 2019 - Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay
Background
Access to an accurate diagnostic test for Buruli ulcer (BU) is a research priority according to the World Health Organization. Nucleic acid amplification of insertion sequence IS2404 by polymerase chain reaction (PCR) is the most sensitive and specific method to detect Mycobacterium ulcerans (M. ulcerans), the causative agent of BU. However, PCR is not always available in endemic communities in Africa due to its cost and technological sophistication. Isothermal DNA amplification systems such as the recombinase polymerase amplification (RPA) have emerged as a molecular diagnostic tool with similar accuracy to PCR but having the advantage of amplifying a template DNA at a constant lower temperature in a shorter time. The aim of this study was to develop RPA for the detection of M. ulcerans and evaluate its use in Buruli ulcer disease.
Methodology and principal findings
A specific fragment of IS2404 of M. ulcerans was amplified within 15 minutes at a constant 42°C using RPA method. The detection limit was 45 copies of IS2404 molecular DNA standard per reaction. The assay was highly specific as all 7 strains of M. ulcerans tested were detected, and no cross reactivity was observed to other mycobacteria or clinically relevant bacteria species. The clinical performance of the M. ulcerans (Mu-RPA) assay was evaluated using DNA extracted from fine needle aspirates or swabs taken from 67 patients in whom BU was suspected and 12 patients with clinically confirmed non-BU lesions. All results were compared to a highly sensitive real-time PCR. The clinical specificity of the Mu-RPA assay was 100% (95% CI, 84–100), whiles the sensitivity was 88% (95% CI, 77–95).
Conclusion
The Mu-RPA assay represents an alternative to PCR, especially in areas with limited infrastructure.
Articles
13Th Edition Of The Edctp Forum To Take Place In Madrid, Spain, From 5 To 9 April 2027
We are delighted to announce that the 13th edition of the EDCTP Forum will be celebrated on 5-9 April 2027, at IFEMA Palacio Municipal in Madrid, Spain.
The event will be co-hosted by the Instituto de Salud Carlos III (ISCIII) under the Spanish Ministry of Science, Innovation and Universities and the Fundación CSAI (FCSAI) under the Ministry of Health, and is co-organised by Global Health EDCTP3 and the EDCTP Association.
Over the past two decades, the biennial European & Developing Countries Clinical Trials Partnership (EDCTP) Forum has evolved to become a cornerstone event for global health research, bringing together leading voices advancing the fight against infectious diseases in sub-Saharan Africa. It showcases the latest scientific breakthroughs, highlights impactful capacity-building efforts, and creates a space for vibrant cross-regional collaboration.
The EDCTP Forum 2027 expects to convene 1,500 participants and stakeholders, from researchers, universities and clinicians to governments, regional bodies, civil society, regulators, and public and private R&D partners, drawing participation primarily from Africa and Europe.
Dr Tuelo Mogashoa Becomes First Tagendi Phd Graduate
Botswana-born scientist Dr Tuelo Mogashoa, a PhD Fellow in the ‘Addressing Gender and Diversity Regional Gaps in Clinical Research Capacity’ (TAGENDI) programme, has successfully defended her PhD in Molecular Biology (Tuberculosis Genomics) at Stellenbosch University. Her virtual oral examination, held on 12 January 2025, marked the culmination of years of research and training.
Her doctoral thesis, titled “Rifampicin- resistant tuberculosis: an emerging threat to human health in Botswana,” addresses one of the most pressing challenges in TB control.
Dr Mogashoa is the first of seven PhD fellows from the inaugural TAGENDI cohort to complete her doctoral studies. The TAGENDI fellowship, implemented under the Trials of Excellence in Southern Africa (TESA) Network, is part of a dedicated PhD fellowship scheme launched by EDCTP2 in 2020 to support women in health research across sub-Saharan Africa. Coordinated by the EDCTP Networks of Excellence, the initiative received funding from the UK National Institute for Health and Care Research (Department of Health and Social Care).
As part of her PhD requirements, Dr Mogashoa was expected to produce four manuscripts, with at least two accepted in peer-reviewed journals. She has exceeded this requirement, publishing three peer-reviewed articles from her doctoral work, with a fourth manuscript currently under review.
Her journey highlights the transformative impact of long-term investment in research training, mentorship, and gender equity. As she moves into the next phase of her career, her work promises to make a meaningful contribution to improving TB diagnosis, treatment, and control.
More information:
- Dr Tuelo Mogashoa Successfully Defends PhD in TB Genomics
- Tuelo’s journey: building Botswana’s capacity for cutting-edge health research
Prof. Novel Chegou Elected As Fellow Of The African Academy Of Sciences
Prof. Novel Chegou, EDCTP Senior Fellow and Acting Head of the Division of Immunology at the Faculty of Medicine and Health Sciences, Stellenbosch University, has been elected as a Fellow of the African Academy of Sciences. This important achievement recognises his scientific leadership and impactful research on tuberculosis, particularly his work on biomarkers to improve diagnosis and patient care in resource-limited settings.
Read more